KR101589317B9 - 안지오텐신 수용체 길항제/차단제 （ａｒｂ） 및 중성 엔도펩티다제 （ｎｅｐ） 억제제의 초구조에 기초한 이중-작용 제약 조성물 - Google Patents

안지오텐신 수용체 길항제/차단제 （ａｒｂ） 및 중성 엔도펩티다제 （ｎｅｐ） 억제제의 초구조에 기초한 이중-작용 제약 조성물

Info

Publication number
KR101589317B9
KR101589317B9 KR1020107009852A KR20107009852A KR101589317B9 KR 101589317 B9 KR101589317 B9 KR 101589317B9 KR 1020107009852 A KR1020107009852 A KR 1020107009852A KR 20107009852 A KR20107009852 A KR 20107009852A KR 101589317 B9 KR101589317 B9 KR 101589317B9
Authority
KR
South Korea
Prior art keywords
superstructures
arb
blocker
dual
pharmaceutical compositions
Prior art date
Application number
KR1020107009852A
Other languages
English (en)
Other versions
KR20100085087A (ko
KR101589317B1 (ko
Inventor
술리만 알-파요우미
지아휘 후
나트라잔 쿠마라페루말
알랜 에드워드 로이스
콜린 루거
에리카 아이나 자누
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40451030&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101589317(B9) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Priority to KR1020157033633A priority Critical patent/KR101700062B1/ko
Publication of KR20100085087A publication Critical patent/KR20100085087A/ko
Application granted granted Critical
Publication of KR101589317B1 publication Critical patent/KR101589317B1/ko
Publication of KR101589317B9 publication Critical patent/KR101589317B9/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020107009852A 2007-11-06 2008-11-04 안지오텐신 수용체 길항제/차단제 （ａｒｂ） 및 중성 엔도펩티다제 （ｎｅｐ） 억제제의 초구조에 기초한 이중-작용 제약 조성물 KR101589317B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020157033633A KR101700062B1 (ko) 2007-11-06 2008-11-04 안지오텐신 수용체 길항제/차단제 （ａｒｂ） 및 중성 엔도펩티다제 （ｎｅｐ） 억제제의 초구조에 기초한 이중-작용 제약 조성물

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98566807P 2007-11-06 2007-11-06
US60/985,668 2007-11-06

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020157033633A Division KR101700062B1 (ko) 2007-11-06 2008-11-04 안지오텐신 수용체 길항제/차단제 （ａｒｂ） 및 중성 엔도펩티다제 （ｎｅｐ） 억제제의 초구조에 기초한 이중-작용 제약 조성물

Publications (3)

Publication Number Publication Date
KR20100085087A KR20100085087A (ko) 2010-07-28
KR101589317B1 KR101589317B1 (ko) 2016-01-28
KR101589317B9 true KR101589317B9 (ko) 2022-11-23

Family

ID=40451030

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020107009852A KR101589317B1 (ko) 2007-11-06 2008-11-04 안지오텐신 수용체 길항제/차단제 （ａｒｂ） 및 중성 엔도펩티다제 （ｎｅｐ） 억제제의 초구조에 기초한 이중-작용 제약 조성물
KR1020157033633A KR101700062B1 (ko) 2007-11-06 2008-11-04 안지오텐신 수용체 길항제/차단제 （ａｒｂ） 및 중성 엔도펩티다제 （ｎｅｐ） 억제제의 초구조에 기초한 이중-작용 제약 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020157033633A KR101700062B1 (ko) 2007-11-06 2008-11-04 안지오텐신 수용체 길항제/차단제 （ａｒｂ） 및 중성 엔도펩티다제 （ｎｅｐ） 억제제의 초구조에 기초한 이중-작용 제약 조성물

Country Status (34)

Country Link
US (3) US20100267786A1 (ko)
EP (4) EP2295035B1 (ko)
JP (2) JP5653218B2 (ko)
KR (2) KR101589317B1 (ko)
CN (2) CN101848700A (ko)
AR (1) AR069184A1 (ko)
AU (1) AU2008324878B2 (ko)
BR (1) BRPI0823505A2 (ko)
CA (1) CA2703598C (ko)
CL (1) CL2008003298A1 (ko)
CY (2) CY1116280T1 (ko)
DK (3) DK3067043T3 (ko)
EC (1) ECSP10010160A (ko)
ES (3) ES2536514T3 (ko)
FI (1) FI3067043T3 (ko)
GT (1) GT201000131A (ko)
HK (3) HK1143529A1 (ko)
HR (3) HRP20230178T3 (ko)
HU (2) HUE028866T2 (ko)
IL (3) IL262990B2 (ko)
JO (1) JOP20080499B1 (ko)
MA (1) MA31797B1 (ko)
MX (1) MX2010004930A (ko)
MY (1) MY153730A (ko)
NZ (1) NZ584686A (ko)
PE (2) PE20141072A1 (ko)
PL (3) PL3067043T3 (ko)
PT (3) PT2217205E (ko)
RU (1) RU2493844C3 (ko)
SG (1) SG185951A1 (ko)
SI (3) SI2217205T1 (ko)
TN (1) TN2010000200A1 (ko)
TW (1) TWI484982B (ko)
WO (1) WO2009061713A1 (ko)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2536514T3 (es) 2007-11-06 2015-05-26 Novartis Ag Composiciones farmacéuticas de doble acción basadas en superestructuras de antagonista/bloqueador de receptores de angiotensina (ARB) y receptor de endopeptidasa neutra (NEP)
MX2011012627A (es) 2009-05-28 2011-12-14 Novartis Ag Derivados aminobutiricos sustituidos como inhibidores de nepralisina.
EP2594557B1 (en) 2009-05-28 2016-08-10 Novartis AG Substituted aminopropionic derivatives as neprilysin inhibitors
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
CA2807830C (en) * 2010-08-24 2018-04-03 Novartis Ag Treatment of hypertension and/or prevention or treatment of heart failure in a mammal receiving anti-coagulant therapy
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
MA37850A1 (fr) 2012-08-24 2018-07-31 Novartis Ag Inhibiteurs de nep pour le traitement de maladies caractérisées par un agrandissement atrial ou une remodélisation atriale
EA026989B1 (ru) 2013-02-14 2017-06-30 Новартис Аг Производные замещенной бисфенилбутановой кислоты в качестве ингибиторов nep с улучшенной in vivo эффективностью
CN105073762B (zh) 2013-02-14 2017-03-08 诺华股份有限公司 作为nep(中性内肽酶)抑制剂的取代的联苯丁酰膦酸衍生物
US20160206597A1 (en) * 2013-08-26 2016-07-21 Toni Lynne Bransford New Use
WO2015028941A1 (en) 2013-08-26 2015-03-05 Novartis Ag New use
WO2015154673A1 (en) * 2014-04-10 2015-10-15 Zhaoyin Wang Novel prodrugs and combinations for treatment of hypertension and cardiovascular diseases
CN105461647B (zh) * 2014-09-28 2018-06-29 四川海思科制药有限公司 缬沙坦沙库比曲三钠盐复合物的固态形式及其制备方法和用途
MX2017007426A (es) 2014-12-08 2018-04-20 Crystal Pharmatech Co Ltd Formas cristalinas de complejo supramolecular trisodico que comprende valsartan y ahu-377 y metodos de las mismas.
CN104473938B (zh) * 2014-12-30 2017-06-09 北京瑞都医药科技有限公司 一种治疗慢性心衰药物及其制备方法
CN104826115A (zh) * 2015-04-19 2015-08-12 浙江巨泰药业有限公司 一种抗心衰药物组合物及其制备方法
HRP20230480T1 (hr) 2015-05-11 2023-07-21 Novartis Ag Režim doziranja sakubitrila i valsartana za liječenje zatajenja srca
US20180140579A1 (en) 2015-05-29 2018-05-24 Novartis Ag Sacubitril and valsartan for treating metabolic disease
CN106309388A (zh) * 2015-06-30 2017-01-11 深圳信立泰药业股份有限公司 一种用于心衰治疗的药物组合物及其制备方法
WO2017006254A1 (en) 2015-07-08 2017-01-12 Novartis Ag Drug combination comprising an angiotensin ii receptor antagonist, a neutral endopeptidase inhibitor and a mineralcorticoid receptor antagonist
CN105997993B (zh) * 2015-07-11 2018-03-30 麦丽芳 一种用于心血管疾病治疗的固体口服型制剂及其制备方法
CN105997994A (zh) * 2015-07-11 2016-10-12 凌莉 一种固体口服型制剂及其制备方法
CN106176724A (zh) * 2015-07-11 2016-12-07 凌莉 一种稳定的固体药物组合物及其制备方法
CN106074421A (zh) * 2015-07-11 2016-11-09 凌莉 一种提高稳定性的药物组合物
CN106176725A (zh) * 2015-07-11 2016-12-07 凌莉 一种提高稳定性的药物组合物及其制备方法和用途
CN106176723A (zh) * 2015-07-11 2016-12-07 凌莉 一种固体药物组合物及其制备方法
WO2017012600A1 (en) 2015-07-20 2017-01-26 Zentiva, K.S. A pharmaceutical composition containing valsartan and sacubitril and methods for preparation and stabilization thereof
CN106389374A (zh) * 2015-08-03 2017-02-15 深圳信立泰药业股份有限公司 一种含有lcz696的药物组合物及其制备方法
JP6598985B2 (ja) 2015-08-28 2019-10-30 ノバルティス アーゲー 新規の使用
WO2017037596A1 (en) * 2015-08-28 2017-03-09 Dr. Reddy's Laboratories Limited Amorphous solid dispersion of lcz-696
WO2017063581A1 (zh) * 2015-10-16 2017-04-20 深圳信立泰药业股份有限公司 一种用于心血管疾病治疗的口服制剂及其制备方法
CN105669581B (zh) * 2015-11-09 2017-03-22 成都苑东生物制药股份有限公司 一种血管紧张受体拮抗剂和中性内肽酶抑制剂复合物
WO2017085573A1 (en) * 2015-11-20 2017-05-26 Lupin Limited Amorphous sacubitril-valsartan complex and process for preparation thereof
CN105330609B (zh) * 2015-12-07 2017-12-22 南京正大天晴制药有限公司 一种制备lcz696的方法
CN105929031B (zh) * 2015-12-18 2018-08-21 重庆两江药物研发中心有限公司 一种血管紧张素受体拮抗剂和nep抑制剂的复合物中杂质的分离方法
CN105935358B (zh) * 2015-12-18 2019-06-07 重庆两江药物研发中心有限公司 一种沙库比曲缬沙坦缓释剂及其制备方法
CN106905253B (zh) * 2015-12-23 2020-01-03 正大天晴药业集团股份有限公司 一种超分子复合物的结晶
US10722471B2 (en) * 2016-02-03 2020-07-28 Novartis Ag Galenic formulations of organic compounds
US20190054069A1 (en) * 2016-02-03 2019-02-21 Novartis Ag New use of a combination of sacubitril and valsartan
CN105748420B (zh) * 2016-03-04 2018-11-06 山东省药学科学院 一种治疗心力衰竭的lcz696缓释骨架片的制备方法
CN105902506A (zh) * 2016-06-12 2016-08-31 佛山市腾瑞医药科技有限公司 一种沙卡布曲缬沙坦制剂及其应用
WO2018069937A1 (en) 2016-10-13 2018-04-19 Mylan Laboratories Limited Solid dispersions of trisodium sacubitril valsartan and process for the preparation thereof
WO2018178295A1 (en) 2017-03-31 2018-10-04 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Stable hot-melt extrudate containing valsartan and sacubitril
ES2890573T3 (es) * 2017-03-31 2022-01-20 Tiefenbacher Alfred E Gmbh & Co Kg Producto extruido de fusión en caliente estable que contiene valsartán y sacubitrilo
WO2018211479A1 (en) 2017-05-19 2018-11-22 Lupin Limited Stabilized compositions of angiotensin ii inhibitors and neutral endopeptidase inhibitors and process for preparation thereof
US11382866B2 (en) 2017-07-06 2022-07-12 Mankind Pharma Ltd. Fixed dose pharmaceutical composition of valsartan and sacubitril
WO2019020706A1 (en) 2017-07-28 2019-01-31 Synthon B.V. PHARMACEUTICAL COMPOSITION COMPRISING SACUBITRIL AND VALSARTAN
WO2019073062A1 (en) 2017-10-13 2019-04-18 Alfred E. Tiefenbacher (Gmbh & Co. Kg) TABLET CONTAINING VALSARTAN AND SACUBITRIL
WO2019180735A1 (en) * 2018-03-19 2019-09-26 Natco Pharma Limited Stable pharmaceutical compositions comprising sacubitril-valsartan complex
US11877576B2 (en) 2018-06-22 2024-01-23 Ideaz, Llc Diphenyl tablets and methods of preparing the same
US20210177803A1 (en) 2018-08-23 2021-06-17 Novartis Ag New pharmaceutical use for the treatment of heart failure
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
EP3766484B1 (en) 2019-07-19 2021-08-25 Zentiva, K.S. Solid pharmaceutical dosage form comprising valsartan and sacubitril
KR102545274B1 (ko) 2020-02-26 2023-06-20 에리슨제약(주) 사쿠비트릴 및 발사르탄을 포함하는 심부전 치료용 서방성 제제, 및 이를 포함하는 다중방출 복합제제와 이의 제조방법
KR20210120560A (ko) 2020-03-27 2021-10-07 주식회사 유영제약 고함량의 주성분을 포함하는 정제 및 그 제조방법
KR20210138510A (ko) 2020-05-12 2021-11-19 에리슨제약(주) 사쿠비트릴, 발사르탄 및 네비보롤을 포함하는 심부전 및 허혈성 심질환의 예방 또는 치료용 약제학적 조성물 및 이를 포함하는 약제학적 복합제제
KR20220091767A (ko) 2020-12-24 2022-07-01 주식회사 보령 사쿠비트릴 발사르탄 하이브리드 화합물 또는 그 약제학적으로 허용되는 염을 유효성분으로 포함하는 약제학적 조성물
KR102486815B1 (ko) 2021-01-20 2023-01-10 주식회사 대웅제약 Nep 저해제 및 arb를 포함하는 약학 조성물 및 이의 제조 방법

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US608220A (en) 1898-08-02 Mechanical movement
US607355A (en) 1898-07-12 Carrier for bicycles
US607893A (en) 1898-07-26 Automatic switch-operating machine
US735093A (en) 1903-01-31 1903-08-04 Oscar Greenwald Elevator-cable guard.
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
US6558699B2 (en) * 1997-11-17 2003-05-06 Smithkline Beecham Corporation High drug load immediate and modified release oral dosage formulations and processes for their manufacture
IL136142A0 (en) * 1997-11-17 2001-05-20 Smithkline Beecham Corp High drug load immediate and modified release oral dosage formulations and processes for their manufacture
US6248729B1 (en) * 1998-06-17 2001-06-19 Bristol-Myers Squibb Co. Combination of an ADP-receptor blocking antiplatelet drug and antihypertensive drug and a method for preventing a cerebral infarction employing such combination
CZ297795B6 (cs) * 1998-12-23 2007-03-28 Novartis Ag Tablety obsahující valsartan
PL205715B1 (pl) 2000-07-19 2010-05-31 Novartis Ag Sól wapniowa walsartanu w postaci tetrahydratu, preparat farmaceutyczny zawierający tę sól, zastosowanie i sposób wytwarzania tej soli
CN1615134A (zh) 2002-01-17 2005-05-11 诺瓦提斯公司 含有缬沙坦和nep抑制剂的药物组合物
US7468390B2 (en) * 2002-01-17 2008-12-23 Novartis Ag Methods of treatment and pharmaceutical composition
JP3751287B2 (ja) * 2002-03-27 2006-03-01 バイエル薬品株式会社 小型化されたニフェジピン有核錠剤
WO2003089417A1 (en) 2002-04-15 2003-10-30 Dr. Reddy's Laboratories Limited Novel crystalline forms of (s)-n-(1-carboxy-2-methyl-prop-1-yl) -n-pentanoyl-n- [2’-(1h-tetrazol-5-yl-)- biphenyl-4-yl methyl] amine (valsartan)
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
DE602004013405T2 (de) 2003-03-17 2009-05-07 Teva Pharmaceutical Industries Ltd. Polymorphe formen von valsartan
EP1648515B1 (en) 2003-07-16 2012-11-21 Boehringer Ingelheim International GmbH Chlorthalidone combinations
GB0402262D0 (en) * 2004-02-02 2004-03-10 Novartis Ag Process for the manufacture of organic compounds
GT200600371A (es) 2005-08-17 2007-03-21 Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas
US20090304755A1 (en) * 2005-10-27 2009-12-10 Raghu Rami Reddy Kasu Pharmaceutical formulation of losartan
US20080227836A1 (en) 2005-10-31 2008-09-18 Lupin Ltd Stable Solid Oral Dosage Forms of Valsartan
CA2628793C (en) 2005-11-07 2015-01-27 Stryker Corporation Patient handling device including local status indication, one-touch fowler angle adjustment, and power-on alarm configuration
WO2007056324A2 (en) 2005-11-08 2007-05-18 Novartis Ag Combination of an angiotensin ii receptor blocker, a calcium channel blocker and another active agent
AR057882A1 (es) * 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
EP1897537A1 (en) * 2006-09-04 2008-03-12 Novartis AG Composition comprising an angiotensin II receptor antagonist
ES2536514T3 (es) 2007-11-06 2015-05-26 Novartis Ag Composiciones farmacéuticas de doble acción basadas en superestructuras de antagonista/bloqueador de receptores de angiotensina (ARB) y receptor de endopeptidasa neutra (NEP)

Also Published As

Publication number Publication date
HRP20160988T1 (hr) 2016-10-07
US20100267786A1 (en) 2010-10-21
IL249922A0 (en) 2017-03-30
JP2011503082A (ja) 2011-01-27
JP2015038069A (ja) 2015-02-26
MA31797B1 (fr) 2010-10-01
HUE028866T2 (en) 2017-01-30
IL262990B1 (en) 2023-06-01
RU2010123027A (ru) 2011-12-20
IL205208A0 (en) 2010-12-30
TN2010000200A1 (en) 2011-11-11
SI2295035T1 (sl) 2016-09-30
PE20091390A1 (es) 2009-10-13
PT3067043T (pt) 2023-03-01
EP2295035A2 (en) 2011-03-16
CY1117883T1 (el) 2017-05-17
EP4186491A1 (en) 2023-05-31
TW200936183A (en) 2009-09-01
CA2703598A1 (en) 2009-05-14
WO2009061713A1 (en) 2009-05-14
AU2008324878A1 (en) 2009-05-14
PT2217205E (pt) 2015-06-08
JOP20080499B1 (ar) 2022-09-15
PL3067043T3 (pl) 2023-05-08
EP2217205B1 (en) 2015-03-04
KR101700062B9 (ko) 2022-11-23
GT201000131A (es) 2012-04-30
EP3067043B1 (en) 2022-11-30
ECSP10010160A (es) 2010-06-29
JP5653218B2 (ja) 2015-01-14
HK1143529A1 (en) 2011-01-07
NZ584686A (en) 2013-03-28
HK1149721A1 (zh) 2011-10-14
HUE061321T2 (hu) 2023-06-28
EP3067043A1 (en) 2016-09-14
RU2493844C3 (ru) 2017-07-05
US20240115536A1 (en) 2024-04-11
HK1224195A1 (zh) 2017-08-18
KR20150139624A (ko) 2015-12-11
US20210085631A1 (en) 2021-03-25
KR20100085087A (ko) 2010-07-28
SG185951A1 (en) 2012-12-28
CA2703598C (en) 2016-08-09
PL2217205T3 (pl) 2015-07-31
AU2008324878B2 (en) 2013-04-18
MY153730A (en) 2015-03-13
CN101848700A (zh) 2010-09-29
CN103251587A (zh) 2013-08-21
ES2536514T3 (es) 2015-05-26
DK2217205T3 (en) 2015-05-11
ES2587336T3 (es) 2016-10-24
HRP20230178T3 (hr) 2023-03-31
EP2217205A1 (en) 2010-08-18
KR101589317B1 (ko) 2016-01-28
PE20141072A1 (es) 2014-09-10
BRPI0823505A2 (pt) 2015-06-16
PL2295035T3 (pl) 2016-11-30
SI2217205T1 (sl) 2015-10-30
AR069184A1 (es) 2010-01-06
MX2010004930A (es) 2010-05-27
CL2008003298A1 (es) 2009-06-26
EP2295035A3 (en) 2012-08-08
DK3067043T3 (da) 2023-02-27
DK2295035T3 (en) 2016-08-29
PT2295035T (pt) 2016-08-22
EP2295035B1 (en) 2016-05-18
KR101700062B1 (ko) 2017-01-26
TWI484982B (zh) 2015-05-21
SI3067043T1 (sl) 2023-04-28
HRP20150459T1 (hr) 2015-07-17
RU2493844C2 (ru) 2013-09-27
IL205208A (en) 2017-01-31
IL262990B2 (en) 2023-10-01
CY1116280T1 (el) 2017-03-15
IL262990A (en) 2018-12-31
FI3067043T3 (fi) 2023-03-18
ES2939163T3 (es) 2023-04-19

Similar Documents

Publication Publication Date Title
IL262990A (en) Dual-activity pharmaceutical compositions based on angiotensin receptor antagonist/blocker (arb) and neutral endopeptidase (nep) inhibitor superstructures
HUS2100003I1 (hu) Angiotenzin receptor antagonista és NEP inhibitor gyógyszerészeti kombinációja
IL194642A0 (en) Antagonist anti-cd40 antibody pharmaceutical compositions
IL197788A0 (en) Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use
HUS1800044I1 (hu) Angiotenzin-II-receptor antagonisták macskák magas vérnyomásának kezelésére
EP2154131A4 (en) INHIBITOR OF THE G-PROTEIN-COUPLED RECEPTOR AND PHARMACEUTICAL PRODUCT
HK1133597A1 (en) Therapeutic compositions comprising a specific endothelin receptor antagonist and a pde5 inhibitor
SI2252273T1 (sl) Trdni farmacevtski sestavek, ki obsega nepeptidni antagonist receptorja angiotenzina II in diuretik
HK1135110A1 (en) Nk1 receptor antagonist composition nk1
GB2464231B (en) Poly-TLR antagonist
ZA200704717B (en) Pharmaceutical combinations of an angiotensin receptor antagonist and an NEP inhibitor

Legal Events

Date Code Title Description
A201 Request for examination
AMND Amendment
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
J201 Request for trial against refusal decision
A107 Divisional application of patent
AMND Amendment
B701 Decision to grant
GRNT Written decision to grant
A101 Application to extend term of patent right by permit
FPAY Annual fee payment

Payment date: 20190103

Year of fee payment: 4

FPAY Annual fee payment

Payment date: 20200103

Year of fee payment: 5

J206 Request for trial to confirm the scope of a patent right
J204 Request for invalidation trial [patent]
J204 Request for invalidation trial [patent]
J206 Request for trial to confirm the scope of a patent right
J121 Written withdrawal of request for trial
J121 Written withdrawal of request for trial
J301 Trial decision

Free format text: TRIAL NUMBER: 2021100001365; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20210507

Effective date: 20220531

Free format text: TRIAL NUMBER: 2021100001364; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20210507

Effective date: 20220531

Free format text: TRIAL NUMBER: 2021100001363; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20210507

Effective date: 20220531

J121 Written withdrawal of request for trial
J301 Trial decision

Free format text: TRIAL NUMBER: 2021100001518; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20210521

Effective date: 20220803

J301 Trial decision

Free format text: TRIAL NUMBER: 2021100001561; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20210521

Effective date: 20220804

Free format text: TRIAL NUMBER: 2021100001547; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20210521

Effective date: 20220804

Free format text: TRIAL NUMBER: 2021100001544; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20210521

Effective date: 20220804

Free format text: TRIAL NUMBER: 2021100001541; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20210521

Effective date: 20220804

Free format text: TRIAL NUMBER: 2021100001538; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20210521

Effective date: 20220804

J301 Trial decision

Free format text: TRIAL NUMBER: 2021100001562; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20210521

Effective date: 20220804

Free format text: TRIAL NUMBER: 2021100001560; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20210521

Effective date: 20220804

Free format text: TRIAL NUMBER: 2021100001559; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20210521

Effective date: 20220804

Free format text: TRIAL NUMBER: 2021100001556; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20210521

Effective date: 20220804

Free format text: TRIAL NUMBER: 2021100001553; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20210521

Effective date: 20220804

Free format text: TRIAL NUMBER: 2021100001550; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20210521

Effective date: 20220804

J301 Trial decision

Free format text: TRIAL NUMBER: 2021100001524; TRIAL DECISION FOR INVALIDATION REQUESTED 20210521

Effective date: 20220809

Free format text: TRIAL NUMBER: 2021100001522; TRIAL DECISION FOR INVALIDATION REQUESTED 20210521

Effective date: 20220809

Free format text: TRIAL NUMBER: 2021100001505; TRIAL DECISION FOR INVALIDATION REQUESTED 20210520

Effective date: 20220809

Free format text: TRIAL NUMBER: 2021100001496; TRIAL DECISION FOR INVALIDATION REQUESTED 20210520

Effective date: 20220809

Free format text: TRIAL NUMBER: 2021100001495; TRIAL DECISION FOR INVALIDATION REQUESTED 20210520

Effective date: 20220809

Free format text: TRIAL NUMBER: 2021100001494; TRIAL DECISION FOR INVALIDATION REQUESTED 20210520

Effective date: 20220809